2001 Targeting Trends Review

Maciejewski-Lenoir D, Heinrichs SC, Liu X-J, Ling N, Tucker A, Xie Q, Lappi DA, Grigoriadis DE (2000) Selective impairment of corticotropin-releasing factor1 (CRF1) receptor-mediated function using CRF coupled to saporin. Endocrinol 141:498-504. doi: 10.1210/endo.141.2.7336

Summary: Corticotropin-releasing factor 1 (CRF1) is a 41-amino acid peptide which mediates many of the body’s behavioral, autonomic, immune, and endocrine responses to stress. Reduced activation of the CRF systems plays a role in a variety of psychiatric and metabolic disease states. Maciejewski-Lenoir et al. have developed a CRF-SAP targeted toxin that can eliminate cells expressing the CRF1 but not CRF2a receptors. These data indicate that CRF-SAP (Cat. #IT-13) may be useful as a tool to examine receptor-selective impairment of CRF system function.

Related Products: CRF-SAP (Cat. #IT-13)

Winkler J, Ramirez GA, Thal LJ, Waite JJ (2000) Nerve growth factor (NGF) augments cortical and hippocampal cholinergic functioning after p75NGF receptor-mediated deafferentation but impairs inhibitory avoidance and induces fear-related behaviors. J Neurosci 20:834-844. doi: 10.1523/JNEUROSCI.20-02-00834.2000

Usage: 192-SAP (Cat. #IT-01) 1.0 or 2.7 µg in 10 µl, intracerebroventricular

Related Products: 192-IgG-SAP (Cat. #IT-01)

Friedrich MJ (2000) Loss of nerve: a molecular approach to better treatment of chronic pain. JAMA 283(2):187-188. doi: 10.1001/jama.283.2.187

Summary: The use of SP-SAP (Cat. #IT-07) as a promising new method for chronic pain relief is discussed in this review article. Chronic pain has classically been treated in ways that frequently have adverse effects on the patient’s quality of life. Friedrich touches on recently developed toxins that are useful in techniques of molecular neurosurgery. These techniques allow the dissection of pain pathways in the brain and spinal cord which will provide not only a greater understanding of these pathways but also potential therapies for chronic pain and other pain conditions.

Related Products: SP-SAP (Cat. #IT-07)

Bassant MH, Poindessous-Jazat F, Schmidt BH (2000) Sustained effect of metrifonate on cerebral glucose metabolism after immunolesion of basal forebrain cholinergic neurons in rats. Eur J Pharmacol 387:151-162. doi: 10.1016/s0014-2999(99)00742-6

Usage: 192-SAP (Cat. #IT-01) 134 ng in 0.2 μl, basal forebrain

Related Products: 192-IgG-SAP (Cat. #IT-01)

Lehmann O, Jeltsch H, Lehnardt O, Pain L, Lazarus C, Cassel JC (2000) Combined lesions of cholinergic and serotonergic neurons in the rat brain using 192 IgG-Saporin and 5,7-dihydroxytryptamine: neurochemical and behavioural characterization. Eur J Neurosci 12:67-79. doi: 10.1046/j.1460-9568.2000.00881.x

Summary: Lesioning of septohippocampal pathways has often been used as a model for Alzheimer’s disease because these lesions alter cognitive capabilities such as spatial memory. Recent work in the behavioral neurosciences has shown that other neurotransmitter systems such as GABAergic, noradrenergic, and serotonergic systems also play a role in learning and memory. Lehmann et al. combined the effects of the cholinergic immunotoxin 192-SAP (Cat. #IT-01) and the serotonergic toxin 5,7-dihydroxytryptamine to examine interactions between these two pathways. The effects of lesioning these two pathways in concert indicate that they both play roles in cognitive functions related to working memory. [192-SAP 2 µg/lateral ventricle]

Related Products: 192-IgG-SAP (Cat. #IT-01)

Sorger D, Schliebs R, Kampfer I, Rossner S, Heinicke J, Dannenberg C, Georgi P (2000) In vivo [125I]-iodobenzovesamicol binding reflects cortical cholinergic deficiency induced by specific immunolesion of rat basal forebrain cholinergic system. Nucl Med Biol 27:23-31. doi: 10.1016/s0969-8051(99)00087-6

Usage: 192-SAP (Cat. #IT-01), 2 µg into each lateral ventricle

Related Products: 192-IgG-SAP (Cat. #IT-01)

Kohls MD, Lappi DA (2000) Mab-ZAP: A tool for evaluating antibody efficacy for use in an immunotoxin. BioTechniques 28(1):162-165. doi: 10.2144/00281pf01

Summary: Immunotoxins are useful tools for elimination of specific cell populations in vitro and in vivo for research and therapeutic applications. One of the factors limiting the use of immunotoxins is the selection of an appropriate antibody. Advanced Targeting Systems has created a reagent that allows researchers to select antibodies with the desired characteristics before an immuntoxin is made, purified, and assayed. Using a goat anti-murine IgG coupled to the ribosome-inactivating protein saporin, researchers can screen hundreds of antibodies in a time and cost-effective manner.

Related Products: Mab-ZAP (Cat. #IT-04), Rab-ZAP (Cat. #IT-05), Hum-ZAP (Cat. #IT-22), Rat-ZAP (Cat. #IT-26), Anti-M-ZAP (Cat. #IT-30), Goat-ZAP (Cat. #IT-36)